集落刺激因子（CSFs）
集落刺激因子（CSF）家族由可溶性糖蛋白组成，它们调控造血祖细胞的存活、增殖和谱系特异性分化，同时激活成熟血细胞。该家族包含四个主要成员：粒细胞-巨噬细胞集落刺激因子（GM-CSF）、巨噬细胞集落刺激因子（M-CSF/CSF-1）、粒细胞集落刺激因子（G-CSF）和多潜能集落刺激因子（IL-3）。GM-CSF、G-CSF和M-CSF通过与不同的α链结合，这些α链偶联于共同的β亚基（GM-CSFRβ）或LIFRβ，触发JAK2-STAT5/3、PI3K-AKT和ERK信号级联，促进髓系细胞向粒细胞、单核细胞/巨噬细胞或树突状细胞定向分化。除造血作用外，CSFs还参与胚胎着床、胎盘发育、组织修复和肿瘤微环境重塑。重组G-CSF（非格司亭）和GM-CSF（沙格司亭）是化疗诱导的中性粒细胞减少症、干细胞动员和免疫增强的标准治疗药物，也是急性放射综合征、白血病和辅助免疫治疗的储备药物。
产品列表
| 靶点 | 产品货号 | 产品名称 | 反应性 | 预测分子量 |
|---|---|---|---|---|
M-CSF | Recombinant Rat M-CSF | Rat | 25.2 kDa | |
GM-CSF (C-6His) | Recombinant Rat GM-CSF (C-6His) | Rat | 15.6 kDa | |
TPO (N-6His) | Recombinant Mouse TPO (N-6His) | Mouse | 36.4 kDa | |
TPO (C-6His) | Recombinant Mouse TPO (C-6His) | Mouse | 36.4 kDa | |
| M-CSF | PHM1141 | Recombinant Mouse M-CSF | Mouse | 26 kDa |
| M-CSF (C-6His) | PHM1125 | Recombinant Mouse M-CSF (C-6His) | Mouse | 27 kDa |
| G-CSF (C-6His) | PHM0758 | Recombinant Mouse G-CSF (C-6His) | Mouse | 19.8 kDa |
| GM-CSF (C-6His) | PHM0748 | Recombinant Mouse GM-CSF (C-6His) | Mouse | 15.1 kDa |
| TPO (N, C-6His) | PHH1637 | Recombinant Human TPO (N, C-6His) | Human | 37.3 kDa |
| M-CSF (C-6His) | PHH1139 | Recombinant Human M-CSF (C-6His) | Human | 26.17 kDa |
| GM-CSF (C-6His) | PHH0749 | Recombinant Human GM-CSF (C-6His) | Human | 15.5 kDa |
| EOP (C-6His) | PHH0605 | Recombinant Human EOP (C-6His) | Human | 19.2 kDa |
| GM-CSF | PEM0750 | Recombinant Mouse GM-CSF | Mouse | 14.2 kDa |
| GM-CSF (E. coli) | PEH0747 | Recombinant Human GM-CSF (E. coli) | Human | 14.6 kDa |
| G-CSF | PEH0720 | Recombinant Human G-CSF | Human | 18.8 kDa |
验证数据
相关产品
参考文献
1. Biology and action of colony--stimulating factor-1. Stanley ER, et al. Mol Reprod Dev.1997. [PMID: 8981357]
2. Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors. El-Gamal MI, et al. J Med Chem. 2018. [PMID: 29293000]
3. Colony-stimulating factor 1 receptor signaling in the central nervous system and the potential of its pharmacological inhibitors to halt the progression of neurological disorders. Tarale P, et al. Inflammopharmacology. 2022. [PMID: 35290551]
